Drug Profile
Research programme: anticancer angiogenesis inhibitors - Sopherion therapeutics
Alternative Names: ST100,059; ST100,068Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sopherion Therapeutics
- Class
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Canada (Intraperitoneal)